OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Exosomes are extracellular vesicles (EVs) that are produced by almost all cells as part of normal physiology and act as naturally-occurring cellular messengers, transporting proteins and nucleic acids as a form of intercellular communication. At Evox we are engineering exosomes to enable specific loading of therapeutic proteins and nucleic acids, with the aim of using these engineered exosomes as potential therapies in inherited metabolic diseases, such as phenylketonuria (PKU) and arginosuccinic aciduria (ASA). By engineering exosome-associated proteins, we can potentially use exosomes to replace mutated proteins in such diseases, either through direct protein replacement or through the deliver of mRNA to target cells.
